



## Memorandum

**To:** Clients / DLS Staff  
**From:** Dr. Wesley J. Kim  
**Date:** May 7, 2012  
**Subject:** B-Natriuretic Peptide

---

B-Natriuretic Peptide (BNP) is synthesized and released into the circulation in response to volume overload or conditions that cause ventricular stretch. Its role is in the control of fluid and electrolyte homeostasis by interacting with the rennin-angiotensin-aldosterone system. BNP has a half-life of approximately 23 minutes, and is cleared from circulation by specific cellular receptors and neutral endopeptidases. Numerous studies have shown that BNP is a useful marker for the diagnosis, prognosis, and therapeutic monitoring of patients with congestive heart failure, and provides prognostic and risk stratification information in patients with acute coronary syndrome (ACS).

Beginning May 21, 2012, DLS will be changing its platform for the measurement of BNP from the current Beckman Access to the new Abbott Architect platform. The Architect BNP assay is a two-step chemiluminescent microparticle immunoassay which provides quantitative measurements of BNP in EDTA plasma. In-house validation studies show excellent precision and good correlation with the current Beckman Access platform, without significant bias. As such, the current reference range is not expected to change, and will remain at < 100 pg/mL.

### Ordering Information

Test Name	Test Code	Specimen Requirement	CPT
B-Natruetic Peptide (BNP)	4283	EDTA plasma	83880

If you have any questions please contact DLS client services at 589-5101 or Dr. Wesley J Kim at 589-5131.